FY2024 · ended Dec 31, 2024 · Revenue $41.09M, +13.9% YoY · Filed Mar 25, 2026
Equillium, Inc. (EQ) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$22.8 million. As of Jun 30, 2026 it held $57.2 million in cash and investments and $584,000 in total debt.
Revenue
$41.09M
+13.9% vs prior year
Net income
$-22.40M
-177.6% vs prior year
Operating cash flow (TTM)
$-19.97M
+9.8% vs year-ago TTM
Free cash flow (TTM)
$-20.09M
+9.3% vs year-ago TTM
EPS
$-0.39
-69.6% vs prior year
Dividend per share
None
Shares outstanding
63.23M
+77.6% vs prior year
Net cash
$56.58M
as of Jun 30, 2026
Operating margin
-20.1%
FY 2024
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- EQ (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- La Jolla, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1746466
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | $41.1M | $36.1M | $15.8M | — |
| Operating income | -$23.6M | -$8.3M | -$14.5M | -$62.1M | -$37.8M |
| Net income | -$22.4M | -$8.1M | -$13.3M | -$62.4M | -$39.1M |
| Diluted EPS | -$0.39 | -$0.23 | -$0.38 | -$1.85 | — |
| Operating cash flow | -$22.7M | -$19.0M | -$21.8M | -$8.7M | -$32.1M |
| Free cash flow | -$22.8M | -$19.1M | -$21.8M | -$9.0M | -$32.1M |
| Total assets | $31.9M | $25.6M | $50.5M | $78.4M | $85.4M |
| Total liabilities | $3.3M | $6.5M | $28.0M | $46.5M | $18.9M |
| Stockholders' equity | $28.6M | $19.1M | $22.6M | $31.9M | $66.5M |
| Cash and investments | $30.3M | $22.6M | $40.9M | $71.0M | $80.7M |
| Total debt | $719,000 | $384,000 | $824,000 | $10.3M | $11.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Unregistered share sale, Regulation FD disclosure, Other events
|
Oct 26, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Other events
|
Oct 5, 2026 | Oct 5, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 29, 2026 | May 28, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
All 465 Equillium, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.